首页> 外文期刊>BMC Nephrology >Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report
【24h】

Focal segmental glomerulosclerosis lesion associated with inhibition of tyrosine kinases by lenvatinib: a case report

机译:lenvatinib抑制酪氨酸激酶相关的局灶节段性肾小球硬化病变:一例报告

获取原文
       

摘要

Lenvatinib is a tyrosine kinase inhibitor with novel binding ability. It is considered the standard of care for metastatic thyroid cancer; moreover, whether it is indicated for other malignant tumors has been examined. Lenvatinib increases the risk of kidney injury in some patients. In comparison with sorafenib, which is a conventional tyrosine kinase inhibitor (TKI), lenvatinib results in more side effects, including hypertension and proteinuria. We describe a case of secondary focal segmental glomerulosclerosis (FSGS) that developed following treatment of metastatic thyroid cancer with lenvatinib and reviewed the mechanisms of renal impairment. We describe a patient with metastatic thyroid cancer who developed hypertension, nephrotic syndrome, and acute kidney injury after 3?months of lenvatinib treatment. Renal biopsy results revealed that 7 of 16 glomeruli indicated complete hyalinization, and that the glomeruli with incomplete hyalinization showed FSGS due to a vascular endothelial disorder and podocyte damage, which seemed to have been induced by lenvatinib treatment. These findings were similar to those of renal impairment treated with conventional TKIs. Although lenvatinib treatment was discontinued, up to 15?months were required to achieve remission of proteinuria, thus leading to chronic kidney disease with hyalinized lesions. To the best of our knowledge, this is the first reported case of secondary FSGS by lenvatinib treatment. Renal impairment treated with TKIs is commonly associated with minimal change nephrotic syndrome/FSGS findings, and it is suggested that renal involvement with TKI is different from that with the vascular endothelial growth factor ligand. Overexpression of c-mip due to TKI causes disorders such as podocyte dysregulation and promotion of apoptosis, which cause FSGS. Lenvatinib may result in FSGS by a similar mechanism with another TKI and could cause irreversible renal impairment; therefore caution must be used. It is essential to monitor blood pressure, urinary findings, and the renal function.
机译:Lenvatinib是一种具有新型结合能力的酪氨酸激酶抑制剂。它被认为是转移性甲状腺癌的治疗标准;此外,已经检查了是否适用于其他恶性肿瘤。 Lenvatinib会增加某些患者肾损伤的风险。与传统的酪氨酸激酶抑制剂(TKI)索拉非尼相比,lenvatinib导致更多的副作用,包括高血压和蛋白尿。我们描述了继发性甲状腺节段性肾小球硬化症(FSGS)的情况,该病例在用lenvatinib治疗转移性甲状腺癌后得到发展,并回顾了肾脏损害的机制。我们描述了一名lenvatinib治疗3个月后发展为高血压,肾病综合征和急性肾损伤的转移性甲状腺癌患者。肾活检结果显示,16个肾小球中有7个表明完全透明化,而不完全透明化的肾小球则由于血管内皮紊乱和足细胞损伤而显示出FSGS,这似乎是由lenvatinib治疗引起的。这些发现与常规TKIs治疗的肾功能损害相似。尽管lenvatinib治疗已中止,但最长需要15个月才能达到蛋白尿的缓解,从而导致慢性肾脏疾病并伴有透明化病变。据我们所知,这是第一个通过lenvatinib治疗继发FSGS的病例。用TKIs治疗的肾功能损害通常与最小变化肾病综合征/ FSGS的发现有关,提示TKIs的肾脏受累与血管内皮生长因子配体的肾脏受累不同。由于TKI导致c-mip的过度表达会导致诸如足细胞失调和凋亡促进等疾病,从而导致FSGS。 Lenvatinib可能通过与另一TKI相似的机制导致FSGS,并可能导致不可逆的肾脏损害。因此,必须谨慎使用。监测血压,尿液发现和肾功能至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号